Cite
The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV).
MLA
Woldemeskel, Bezawit A., et al. “The BNT162b2 MRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV).” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 74, no. 7, Apr. 2022, pp. 1268–70. EBSCOhost, https://doi.org/10.1093/cid/ciab648.
APA
Woldemeskel, B. A., Karaba, A. H., Garliss, C. C., Beck, E. J., Wang, K. H., Laeyendecker, O., Cox, A. L., & Blankson, J. N. (2022). The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 74(7), 1268–1270. https://doi.org/10.1093/cid/ciab648
Chicago
Woldemeskel, Bezawit A, Andrew H Karaba, Caroline C Garliss, Evan J Beck, Kristy H Wang, Oliver Laeyendecker, Andrea L Cox, and Joel N Blankson. 2022. “The BNT162b2 MRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV).” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 74 (7): 1268–70. doi:10.1093/cid/ciab648.